Risdiplam for treating spinal muscular atrophy

Equality Impact Assessment (Guidance development) (PDF 166 KB)

Register of interests (PDF 164 KB)

Final draft guidance

Final appraisal document (PDF 331 KB)

Committee papers (PDF 2.56 MB)

Public committee slides (PDF 1.45 MB)

Final appraisal document Managed Access  Agreement (PDF 270 KB)

Final appraisal document Data Collection Arrangement (PDF 246 KB)

Final appraisal document Appendix A - Using other treatments after onasemnogene (PDF 129 KB)

Final appraisal document Appendix B - Managed Access Patient Agreement form (PDF 110 KB)

Draft guidance

Appraisal consultation document (PDF version) (PDF 321 KB)

Appraisal consultation document (online commenting)

Committee papers (PDF 5.48 MB)

Public committee slides (PDF 1.12 MB)

Final scope (PDF 195 KB)

Final stakeholder list (PDF 214 KB)

NICE's response to comments on the draft scope and provisional stakeholder list (PDF 848 KB)

Equality impact assessment (Scoping) (PDF 127 KB)

Draft scope pre referral (PDF 215 KB)

Draft matrix pre referral (PDF 230 KB)